Patents by Inventor Thomas Jentsch

Thomas Jentsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LRRC8 proteins and protein complexes and methods for identification of channel modulators
    Patent number: 9927423
    Abstract: The invention relates to a method for the identification of a channel modulator, such as an agonist or antagonist, that interacts with one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E and/or protein complexes thereof. The invention further relates to an isolated heteromeric protein complex comprising one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E for use in such methods, in addition to kits suitable for carrying out such methods. The invention therefore relate preferably to the use of LRRC8 proteins and complexes thereof for the identification of VRAC (VSOAC) modulators.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 27, 2018
    Assignees: FORSCHUNGSVERBUND BERLIN E.V., MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
    Inventors: Thomas Jentsch, Tobias Stauber, Felizia K. Voss
  • LRRC8 PROTEINS AND PROTEIN COMPLEXES AND METHODS FOR IDENTIFICATION OF CHANNEL MODULATORS
    Publication number: 20150253303
    Abstract: The invention relates to a method for the identification of a channel modulator, such as an agonist or antagonist, that interacts with one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E and/or protein complexes thereof. The invention further relates to an isolated heteromeric protein complex comprising one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E for use in such methods, in addition to kits suitable for carrying out such methods. The invention therefore relate preferably to the use of LRRC8 proteins and complexes thereof for the identification of VRAC (VSOAC) modulators.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 10, 2015
    Inventors: Thomas Jentsch, Tobias Stauber, Felizia K. Voss
  • Screening compounds for activity in modulating chloride ion transport
    Patent number: 7851165
    Abstract: A method for screening a test compound for activity in modulating the activity of the chloride channel ClC-7 either directly or by modulating the subcellular localization of Ostm1 comprises determining whether test compound inhibits the binding of Ostm1 to ClC-7. Compounds active in the screen are candidates for use in treating bone resorption conditions such as Osteoporosis by modulating the activity of osteoclasts.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: December 14, 2010
    Assignee: Pharmos Bioscience A/S
    Inventors: Philipp Lange, Jens C. Fuhrmann, Thomas Jentsch
  • Screening Compounds for Activity in Modulating Chloride Ion Transport
    Publication number: 20090170127
    Abstract: A method for screening a test compound for activity in modulating the activity of the chloride channel ClC-7 either directly or by modulating the subcellular localization of Ostm1 comprises determining whether test compound inhibits the binding of Ostm1 to ClC-7. Compounds active in the screen are candidates for use in treating bone resorption conditions such as Osteoporosis by modulating the activity of osteoclasts.
    Type: Application
    Filed: December 18, 2006
    Publication date: July 2, 2009
    Applicant: PHARMOS BIOSCIENCE A/S
    Inventors: Philipp Lange, Jens C. Fuhrmann, Thomas Jentsch
  • Potassium channels and genes encoding these potassium channels
    Publication number: 20050037460
    Abstract: This invention relates to novel potassium channels and genes encoding these channels. More specifically the invention provides isolated polynucleotides encoding the KCNQ4 potassium channel, cells transformed with these polynucleotides, transgenic animals comprising genetic mutations, and the use of the transformed cells and the transgenic animals for the in vitro and in vivo screening of drugs affecting KCNQ4 containing potassium channels.
    Type: Application
    Filed: May 20, 2004
    Publication date: February 17, 2005
    Applicant: NeuroSearch A/S
    Inventor: Thomas Jentsch